TABLE 2.
Change in methylation predicting change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5).
| Gene (sites tested) | Relation to Island | Genomic location | Change type (post–pre) | Sig. sites (p < 0.05) | B | Survive FDR |
| CRHR1 (86) | ||||||
| cg08276280 | os | chr17:43743868 | Δ | 0.005 | 42.12 | Yes |
| cg07657976 | os | chr17:43887205 | Δ | 0.006 | 14.64 | ∼ |
| cg13947929 | ssr | chr17:43863356 | Δ | 0.016 | 31.72 | ∼ |
| cg03423935 | nsr | chr17:43697902 | Δ | 0.026 | 21.71 | ∼ |
| cg18090064 | os | chr17:43716542 | Δ | 0.036 | 12.93 | ∼ |
| cg08119837 | os | chr17:43837500 | Δ | 0.038 | 11.87 | ∼ |
| cg24394631 | ssr | chr17:43863000 | Δ | 0.046 | −21.22 | ∼ |
| cg23420656 | ssf | chr17:43865031 | absΔ | 0.008 | 29.90 | ∼ |
| cg14297797 | os | chr17:43867801 | absΔ | 0.011 | −17.73 | ∼ |
| cg22046703 | nsr | chr17:43860472 | absΔ | 0.011 | 73.01 | ∼ |
| cg13521908 | is | chr17:43861682 | absΔ | 0.012 | −22.14 | ∼ |
| cg06537391 | os | chr17:43799898 | absΔ | 0.014 | 38.30 | ∼ |
| cg05087823 | os | chr17:43835721 | absΔ | 0.021 | 50.67 | ∼ |
| cg10106856 | os | chr17:43880210 | absΔ | 0.024 | 27.08 | ∼ |
| cg04194664 | os | chr17:43716617 | absΔ | 0.028 | −15.52 | ∼ |
| cg15117716 | os | chr17:43871537 | absΔ | 0.038 | −15.71 | ∼ |
| cg12577105 | is | chr17:43860685 | absΔ | 0.042 | 19.27 | ∼ |
| FKBP5 (59) | ∼ | |||||
| cg16012111 | is | chr6:35656758 | Δ | 0.012 | 32.52 | ∼ |
| cg07485685 | is | chr6:35696061 | Δ | 0.024 | 16.92 | ∼ |
| cg14339974 | os | chr6:35687310 | Δ | 0.026 | −7.23 | ∼ |
| cg04791658 | os | chr6:35611554 | Δ | 0.035 | −31.09 | ∼ |
| cg07633853 | os | chr6:35569471 | Δ | 0.036 | 12.64 | ∼ |
| cg06409316 | os | chr6:35642470 | Δ | 0.039 | 9.03 | ∼ |
| cg09318204 | os | chr6:35511434 | Δ | 0.043 | 20.58 | ∼ |
| cg08586216 | os | chr6:35612351 | Δ | 0.049 | 14.08 | ∼ |
| cg16005389 | os | chr6:35592694 | absΔ | 0.010 | 23.15 | ∼ |
| NR3C1 (114) | ∼ | |||||
| cg26222722 | os | chr5:142825390 | Δ | 0.003 | 19.32 | ∼ |
| cg07733851 | nsr | chr5:142781498 | Δ | 0.023 | 18.93 | ∼ |
| cg14621978 | os | chr5:142735238 | Δ | 0.027 | 11.86 | ∼ |
| cg08423118 | os | chr5:142808610 | Δ | 0.034 | −15.39 | ∼ |
| cg01751279 | os | chr5:142793924 | Δ | 0.052 | 8.33 | ∼ |
| cg01391283 | os | chr5:142907714 | absΔ | 0.002 | 41.88 | Yes |
| cg03746860 | os | chr5:142759375 | absΔ | 0.009 | 26.42 | ∼ |
| cg06770322 | os | chr5:142851098 | absΔ | 0.013 | −25.25 | ∼ |
| cg06613263 | nsf | chr5:142779552 | absΔ | 0.031 | −25.46 | ∼ |
| cg11022710 | os | chr5:142820479 | absΔ | 0.036 | 37.00 | ∼ |
| cg11152298 | is | chr5:142783383 | absΔ | 0.047 | −49.83 | ∼ |
| cg01751279 | os | chr5:142793924 | absΔ | 0.047 | 9.54 | ∼ |
os = open sea; is = island; nsr = north shore; ssr = south shore; nsf = north shelf; ssf = south shelf; bold font indicates significantly more methylation change in the MDMA group compared to placebo. A positive direction indicates patients who decrease in symptoms also decrease in methylation; a negative direction indicates patients who decrease in symptoms increase in methylation.